Generic Xelstrym Availability
Last updated on Sep 11, 2024.
Xelstrym is a brand name of dextroamphetamine, approved by the FDA in the following formulation(s):
XELSTRYM (dextroamphetamine - system;transdermal)
-
Manufacturer: NOVEN PHARMS INC
Approval date: March 22, 2022
Strength(s): 4.5MG/9HR [RLD], 9MG/9HR [RLD], 13.5MG/9HR [RLD], 18MG/9HR [RLD]
Has a generic version of Xelstrym been approved?
No. There is currently no therapeutically equivalent version of Xelstrym available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xelstrym. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Patent 11,559,501
Patent expiration dates:
- January 6, 2042✓
- January 6, 2042
-
Transdermal drug delivery device including an occlusive backing
Patent 8,591,941
Issued: November 26, 2013
Inventor(s): Kanios David & Mantelle Juan A. & Nguyen Viet
Assignee(s): Noven Pharmaceuticals, Inc.A transdermal drug delivery system for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric backing layer which can control the delivery rate and profile of the transdermal drug delivery system by adjusting the moisture vapor transmission rate of the polymeric backing layer.
Patent expiration dates:
- October 7, 2025✓
- October 7, 2025
-
Device for transdermal administration of drugs including acrylic polymers
Patent 8,632,802
Issued: January 21, 2014
Inventor(s): Kanios David
Assignee(s): Noven Pharmaceuticals, Inc.A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Patent expiration dates:
- October 7, 2025✓
- October 7, 2025
-
Device for transdermal administration of drugs including acrylic polymers
Patent 9,034,370
Issued: May 19, 2015
Inventor(s): Kanios David
Assignee(s): NOVEN PHARMACEUTICALS, INC.A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.
Patent expiration dates:
- October 7, 2025✓
- October 7, 2025
-
Compositions and methods for transdermal delivery of amphetamine
Patent 9,456,993
Issued: October 4, 2016
Inventor(s): Lambert Robert L.
Assignee(s): NOVEN PHARMACEUTICALS, INC.Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
Patent expiration dates:
- October 24, 2033✓✓
- October 24, 2033
-
Compositions and methods for transdermal delivery of amphetamine
Patent 9,474,722
Issued: October 25, 2016
Inventor(s): Lambert Robert L.
Assignee(s): NOVEN PHARMACEUTICALS, INC.Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
Patent expiration dates:
- October 24, 2033✓
- October 24, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 22, 2025 - NEW PRODUCT
More about Xelstrym (dextroamphetamine)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (6)
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CNS stimulants
- Breastfeeding
- En español
Patient resources
Other brands
Dexedrine, Zenzedi, Dextrostat, ProCentra, Liquadd
Professional resources
Other brands
Dexedrine, Zenzedi, Dextrostat, ProCentra
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.